[New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer]

Laure Blondet; Matthieu Sarabi

doi:10.1016/j.bulcan.2023.04.004

[New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer]

Bull Cancer. 2023 Jul-Aug;110(7-8):742-744. doi: 10.1016/j.bulcan.2023.04.004. Epub 2023 May 17.

[Article in French]

Authors

Laure Blondet¹, Matthieu Sarabi²

Affiliations

¹ Hôpital Saint-Antoine, service d'oncologie médicale, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: Laure.blondet03@gmail.com.
² UMR Inserm 1052/CNRS 5286, centre Léon-Bérard (Lyon), centre de recherche contre le cancer de Lyon, département de cancérologie médicale, groupe oncologie et endoscopie digestive, Cancer Immune Surveillance and Therapeutic Targeting (CISTAR), Lyon, France.

PMID: 37208249
DOI: 10.1016/j.bulcan.2023.04.004

No abstract available

Keywords: Biliary tract cancer; Cancer voies biliaires; Durvalumab; First-line; Immunotherapy; Immunothérapie; Non résécable; Première ligne; Unresectable.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bile Duct Neoplasms* / drug therapy
Cisplatin
Drug Approval
Gemcitabine*
Humans
Treatment Outcome

Substances

Gemcitabine
Cisplatin
durvalumab